Search results for "cop"

showing 10 items of 25502 documents

CCDC 248619: Experimental Crystal Structure Determination

2005

Related Article: D.C.de C.Gomes, H.O.Stumpf, F.Lloret, M.Julve, V.Gonzalez, H.Adams, J.A.Thomas|2005|Inorg.Chim.Acta|358|1113|doi:10.1016/j.ica.2004.10.038

(mu~2~-Sulfato)-diaqua-bis(N-(2-pyrimidylcarbonyl)-2-pyrimidinecarboxamido)-di-copper(ii) monohydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates

researchProduct

CCDC 898735: Experimental Crystal Structure Determination

2013

Related Article: A.E.Ion, S.Nica, A.M.Madalan, F.Lloret, M.Julve, M.Andruh|2013|CrystEngComm|15|294|doi:10.1039/c2ce26469b

(mu~3~-246-Tris(((2-(dimethylamino)ethyl)imino)methyl)benzene-135-triolato)-tris(hydroxy(phenyl)acetato)-tri-copper diethyl ether solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates

researchProduct

CCDC 723744: Experimental Crystal Structure Determination

2010

Related Article: A.Gonzalez-Alvarez, I.Alfonso, J.Cano, P.Diaz, V.Gotor, V.Gotor-Fernandez, E.Garcia-Espana, S.Garcia-Granda, H.R.Jimenez, F.Lloret|2009|Angew.Chem.,Int.Ed.|48|6055|doi:10.1002/anie.200901888

(mu~3~-359111517-Hexa-aza-1713(26)-tripyridina-41016(12)-tricyclohexanacyclooctadecaphane)-bis(mu~3~-hydroxo)-tri-copper(ii) dichloride diperchlorate pentahydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates

researchProduct

CCDC 883708: Experimental Crystal Structure Determination

2013

Related Article: Julia R. Shakirova, Elena V. Grachova, Alexei S. Melnikov, Vladislav V. Gurzhiy, Sergey P. Tunik, Matti Haukka, Tapani A. Pakkanen, and Igor O. Koshevoy|2013|Organometallics|32|4061|doi:10.1021/om301100v

(mu~3~-tris(Diphenylphosphino)methane)-bis(mu~2~-eta^2^-3-hydroxy-33-diphenylprop-1-yn-1-yl)-bromo-(3-hydroxy-33-diphenylprop-1-yn-1-yl)-copper-tri-gold acetone solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates

researchProduct

CCDC 955946: Experimental Crystal Structure Determination

2013

(mu~3~-tris(Diphenylphosphino)methane)-bis(mu~2~-eta^2^-3-hydroxy-33-diphenylprop-1-yn-1-yl)-chloro-(3-hydroxy-33-diphenylprop-1-yn-1-yl)-copper-tri-gold acetone solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates

researchProduct

CCDC 955945: Experimental Crystal Structure Determination

2013

(mu~3~-tris(Diphenylphosphino)methane)-tris(mu~2~-eta^2^-cyclohexylethynyl)-copper-tri-gold hexafluorophosphate dichloromethane solvateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates

researchProduct

CCDC 711358: Experimental Crystal Structure Determination

2010

Related Article: E.Pardo, D.Cangussu, R.Lescouezec, Y.Journaux, J.Pasan, F.S.Delgado, C.Ruiz-Perez, R.Ruiz-Garcia, J.Cano, M.Julve, F.Lloret|2009|Inorg.Chem.|48|4661|doi:10.1021/ic900055d

(mu~4~-NN'-(14-Phenylene)-bis(oxamato))-tetrakis(bis(3-aminopropyl)amine)-tetra-copper(ii) tetraperchlorate dihydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates

researchProduct

CCDC 927862: Experimental Crystal Structure Determination

2013

Related Article: Walter Cañon-Mancisidor, Carlos J. Gómez-García, Guillermo Mínguez Espallargas, Andres Vega, Evgenia Spodine, Diego Venegas-Yazigi, Eugenio Coronado|2014|Chemical Science|5|324|doi:10.1039/C3SC52628C

(mu~6~-Fluoro)-bis(mu~3~-methoxo)-hexakis(mu~2~-35-dimethylpyrazolato)-(mu~2~-hydroxo)-bis(mu~2~-methoxo)-hexa-copperSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates

researchProduct

Superconducting size effect in thin films under electric field: Mean-field self-consistent model

2019

We consider effects of an externally applied electrostatic field on superconductivity, self-consistently within a BCS mean field model, for a clean 3D metal thin film. The electrostatic change in superconducting condensation energy scales as $\mu^{-1}$ close to subband edges as a function of the Fermi energy $\mu$, and follows 3D scaling $\mu^{-2}$ away from them. We discuss nonlinearities beyond gate effect, and contrast results to recent experiments.

---Josephson effectsuprajohtavuusFOS: Physical sciences02 engineering and technology01 natural sciencessuprajohteetSuperconductivity (cond-mat.supr-con)superconducting phase transitionElectric fieldCondensed Matter::Superconductivity0103 physical sciencesThin film010306 general physicsScalingCondensed Matter::Quantum GasesSuperconductivityPhysicsCondensed matter physicsCondensed Matter - SuperconductivityFermi energy021001 nanoscience & nanotechnologyMean field theorythin filmsmesoscopicsohutkalvot0210 nano-technologyEnergy (signal processing)Physical Review B

researchProduct

Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study.

2011

BACKGROUND: Although the association between multimorbidity and polypharmacy has been clearly documented, no study has analyzed whether or not specific combinations of diseases influence the prescription of polypharmacy in older persons. We assessed which clusters of diseases are associated with polypharmacy in acute-care elderly in-patients. METHODS: This cross-sectional study was held in 38 Italian internal medicine and geriatric wards participating in the Registro Politerapie SIMI (REPOSI) study during 2008. The study sample included 1155 in-patients aged 65 years or older. Clusters of diseases, defined as two or more co-occurring specific chronic diseases, were identified using the odds…

---Lung DiseasesMaleSettore MED/09 - Medicina InternaCross-sectional studyGastrointestinal DiseasesComorbidityRisk FactorsNeoplasmsPrevalenceCluster AnalysisHospitalized elderlyclustersGeriatricsAged 80 and overCOPDREPOSISettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheHospitalization---; clusters; polypharmacy; REPOSI; elderlyCardiovascular DiseasesFemalemedicine.medical_specialtyEndocrine System DiseaseselderlyCluster of diseasesInternal medicineDiabetes mellitusmedicineDiabetes MellitusInternal MedicineMultimorbidityHumansCluster of diseases; Hospitalized elderly; PolypharmacyAgedPolypharmacybusiness.industryPolypharmacy Cluster of diseases Hospitalized elderlyOdds ratiomedicine.diseaseComorbidityCross-Sectional StudiesLogistic ModelsGeriatricsPhysical therapyPolypharmacyDementiaMorbiditybusinessEuropean journal of internal medicine

researchProduct